ClinicalTrials.gg
CompletedNCT01265823Updated Mar 11, 2013Results posted

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

A Phase 4 interventional study of Adalimumab in Psoriasis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 8 sites in Mexico. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-03-11.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
23rd of 48
150 · median 148
Started
2010
with 3 others
Phase 4
11 of 48
2 open now
Registered
17th of 48
by date
Lead sponsor
6 of 48
AbbVie (prior sponsor, Abbott)

Among the 48 studies testing adalimumab in Psoriasis, this one is the 23rd largest by enrollment, is one of 4 that started in 2010, is one of 11 in phase 4, and was the 17th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional systemic psoriasis treatment or who are candidates for systemic therapy.

Read the detailed description

Up to 150 subjects having a diagnosis of active plaque psoriasis and fulfilling the study eligibility criteria were enrolled in Mexico. Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at week 1 until week 15). The study drug was self administered via subcutaneous (sc) injection. Safety and efficacy measures were performed throughout the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Humira
  • Adalimumab
  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written prior to any study related procedures and to comply with the requirements of the study protocol
  2. Male and female subjects between 18 and 75 years old
  3. Diagnosis of moderate to severe types I and II plaque psoriasis (Type I : symptoms onset before 40 years old; Type II: symptoms onset after 40 years old), with at least 6 months of duration
  4. Documented moderate to severe plaque psoriasis based on Psoriasis Area and Severity Index (PASI) score >10
  5. Subjects naïve to adalimumab therapy
  6. Subject must be evaluated for active and latent tuberculosis (TB) infection by using a Purified Protein Derivative (PPD) skin test, chest x-ray (posterior to anterior (PA) and lateral views) and a detailed review of the subject's medical history. This screening must be negative
  7. A negative pregnancy test (serum human chorionic gonadotrophin) for women of prior to start of study treatment. (Non-childbearing potential is defined as for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy])
  8. Able and willing to self-administer subcutaneous injections or have available a suitable person to administer subcutaneous injections
  9. Subject is judged to be in generally good health as determined by the investigator

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any agent within 30 days, or five half-lives of the product, which ever is longer. Subject has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or five half lives (whichever is longer) of the drug prior to study entry (Baseline Visit)
  2. Subject has other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with the evaluation of psoriasis or compromise the subject's safety
  3. Subject has a history of dysplasia, (including lymphoma and leukemia), or lymphoproliferative disease other than: a. Successfully and completely treated non- squamous or basal cell carcinoma of the skin with no recurrence within the last five years. b. Localized carcinoma in situ of the cervix or cervical dysplasia, with no recurrence within the last five years
  4. Persistent or recurrent infections or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days, or oral antibiotics, oral antivirals or oral antifungals within 14 days prior to Baseline Visit
  5. Other medical conditions: uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (NYHA) III-IV, recent stroke (within three months), chronic leg ulcer and any other condition (e.g., indwelling urinary catheter) which, in the opinion of the investigator, may place the subject at risk
  6. Previous diagnosis or signs highly indicative of central nervous system demyelinating diseases (e.g., optic neuritis, ataxia, apraxia)
  7. History of listeriosis, histoplasmosis, chronic or active infection, (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active TB
  8. Female subjects who are pregnant or breast-feeding
  9. History of drug or alcohol abuse in the last year
  10. Subject started receiving a new topical therapy within the last four weeks prior to the Baseline visit for areas other than the palms, soles of feet, axilla and groin
  11. Subject started being treated with ultraviolet B (UVB) phototherapy, within the last four weeks prior to the Baseline visit
  12. Subject was treated with psoralen ultraviolet A (PUVA) phototherapy within the last four weeks prior to the Baseline visit
  13. Subject has been initiated on a new systemic agent within the last four weeks prior to the Baseline visit
  14. Patients with history of atopy
  15. Patients with any other disease such as systemic lupus erythematosus (SLE) , Sdx Sjögren, vasculitis etc
  16. Known to the of adalimumab as stated in the label
  17. Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
  18. Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study
  19. Subject with any prior exposure to Tysabri (natalizumab), or Orencia (abatacept)
  20. Subjects with positive immunologic test for hepatitis A, B or C (Positive test of any of the following: hepatitis A viral antibody immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or virus antibody (HCV Ab)
  21. Subjects with a positive immunologic test for HIV determined by enzyme-linked immunosorbent assay (ELISA) method
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 4

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 4. The improvement in PASI score was used as a measure of efficacy.

    Time frame: Week 4

  2. Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy.

    Time frame: Week 16

  3. Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 4

    Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score \<6 indicates that psoriasis has small or no effect at all on participant's life.

    Time frame: Week 4

  4. Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 16

    Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score \<6 indicates that psoriasis has small or no effect at all on participant's life.

    Time frame: Week 16

Secondary outcomes

  1. Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 4

    Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired.

    Time frame: Baseline, Week 4

  2. Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 16

    Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired.

    Time frame: Baseline, Week 16

  3. Dermatology Life Quality Index (DLQI) Categories at Week 4

    Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0-1 no effect at all; 2-5 small effect; 6-10 moderate effect; 11-20 very large effect; 21-30 extremely large effect.

    Time frame: Week 4

  4. Dermatology Life Quality Index (DLQI) Categories at Week 16

    Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0-1 no effect at all; 2-5 small effect; 6-10 moderate effect; 11-20 very large effect; 21-30 extremely large effect.

    Time frame: Week 16

  5. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 4

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-50, 90, and 100 responses are the percentage of participants who achieved at least a 50%, 90%, or 100% reduction (improvement) from baseline in PASI score at Week 4. 100% reduction was considered complete clearance of psoriasis.

    Time frame: Week 4

  6. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-50, 90, and 100 responses are the percentage of participants who achieved at least a 50%, 90%, or 100% reduction (improvement) from baseline in PASI score at Week 4. 100% reduction was considered complete clearance of psoriasis.

    Time frame: Week 16

  7. Physician's Global Assessment (PGA) at Week 4

    The PGA is a 7-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant. Categories are as follows: Severe = very marked plaque elevation, scaling, and/or erythema; Moderate to severe = marked plaque elevation, scaling, and/or erythema; Moderate = moderate plaque elevation, scaling, and/or erythema; Mild to moderate = intermediate between moderate and mild; Mild = slight plaque elevation, scaling, and/or erythema; Almost clear = intermediate between mild and clear; Clear = no signs of psoriasis (post-inflammatory hypopigmentation or hyperpigmentation could be present).

    Time frame: Week 4

  8. Physician's Global Assessment (PGA) at Week 16

    The PGA is a 7-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant. Categories are as follows: Severe = very marked plaque elevation, scaling, and/or erythema; Moderate to severe = marked plaque elevation, scaling, and/or erythema; Moderate = moderate plaque elevation, scaling, and/or erythema; Mild to moderate = intermediate between moderate and mild; Mild = slight plaque elevation, scaling, and/or erythema; Almost clear = intermediate between mild and clear; Clear = no signs of psoriasis (post-inflammatory hypopigmentation or hyperpigmentation could be present). The number of participants who achieve a PGA of 'clear' or 'almost clear' at Week 16 was a secondary outcome measure in this study.

    Time frame: Week 16

  9. Mean Lipid Profile, Triglycerides, and C-Reactive Protein (CRP) at Baseline and Week 16

    Normal values: C-reactive protein (CRP) 0-0.79 mg/dL; cholesterol 30-199 mg/dL; high density lipoprotein (HDL) 40-100 mg/dL; very low density lipoprotein (VLDL) 0-34 mg/dL; low density lipoprotein (LDL) 20-99 mg/dL; triglycerides 50-149 mg/dL.

    Time frame: Baseline, Week 16

  10. Mean Homocysteine Levels at Baseline and Week 16

    Normal values for homocysteine were 5-13.9 µmol/L.

    Time frame: Baseline, Week 16

  11. Percentage of Obese vs. Non-obese (Per Body Mass Index [BMI]) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16

    The Body Mass Index (BMI) was used to determine the groups of participants who were overweight and who were considered obese. A BMI of 18.5 to 25 was considered normal range, 25 to 30 as overweight and 30 and above as obesity, in both men and women. Response to treatment in participants with obesity (based on Body Mass Index) versus those without obesity was assessed via PASI-75 response (see Outcome Measure 1 for details) and DLQI score of \<6 (see Outcome Measure 3 for details).

    Time frame: Week 16

  12. Percentage of Obese vs. Non-obese (Per Waist-Hip Ratio) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16

    The Waist-Hip Ratio was used to determine the groups of participants who were overweight and who were considered obese. Obesity was defined as a ratio of \>1 for men and \>0.8 for women. Response to treatment in participants with obesity (based on Waist-Hip Ratio) versus those without obesity was assessed via PASI-75 response (see Outcome Measure 1 for details) and DLQI score of \<6 (see Outcome Measure 3 for details).

    Time frame: Week 16

  13. Serum Levels of Folic Acid at Baseline and Week 4

    Normal values for folic acid were 3-15 ng/mL.

    Time frame: Baseline, Week 4

  14. Serum Levels of Vitamin B6 at Baseline and Week 4

    Normal values for vitamin B6 were 18-175 nmol/L.

    Time frame: Baseline, Week 4

  15. Serum Levels of Vitamin B12 at Baseline and Week 4

    Normal values for vitamin B12 were 200-1100 pg/mL.

    Time frame: Baseline, Week 4

  16. Serum Levels of Folic Acid at Baseline and Week 16

    Normal values for folic acid were 3-15 ng/mL.

    Time frame: Baseline, Week 16

  17. Serum Levels of Vitamin B6 at Baseline and Week 16

    Normal values for vitamin B6 were 18-175 nmol/L.

    Time frame: Baseline, Week 16

  18. Serum Levels of Vitamin B12 at Baseline and Week 16

    Normal values for vitamin B12 were 200-1100 pg/mL.

    Time frame: Baseline, Week 16

07

Results

Posted Mar 11, 2013

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started150
Completed143
Not completed7
Withdrew: Unsatisfactory response efficacy1
Withdrew: Failure to return4
Withdrew: Protocol violation1
Withdrew: Participant request1

Outcome measures

PrimaryPercentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 4

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 4. The improvement in PASI score was used as a measure of efficacy.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 4
percentage of participantsAdalimumab
Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 431
PrimaryPercentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 16
percentage of participantsAdalimumab
Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 1685
PrimaryPercentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 4

Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score \<6 indicates that psoriasis has small or no effect at all on participant's life.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 4
percentage of participantsAdalimumab
Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 465
PrimaryPercentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 16

Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score \<6 indicates that psoriasis has small or no effect at all on participant's life.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 16
percentage of participantsAdalimumab
Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 1686
SecondaryMean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 4

Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired.

Time frame:
Baseline, Week 4
Reported as:
Mean · units on a scale
Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 4
units on a scaleAdalimumab
Score at Baseline11.7 ± 6.3
Score at Week 45.2 ± 6.4
SecondaryMean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 16

Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 16
units on a scaleAdalimumab
Score at Baseline11.7 ± 6.3
Score at Week 161.8 ± 2.0
SecondaryDermatology Life Quality Index (DLQI) Categories at Week 4

Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0-1 no effect at all; 2-5 small effect; 6-10 moderate effect; 11-20 very large effect; 21-30 extremely large effect.

Time frame:
Week 4
Reported as:
Number · participants
Dermatology Life Quality Index (DLQI) Categories at Week 4
participantsAdalimumab
No Effect42
Small Effect52
Moderate Effect32
Very Large Effect18
Extremely Large Effect3
Missing3
SecondaryDermatology Life Quality Index (DLQI) Categories at Week 16

Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0-1 no effect at all; 2-5 small effect; 6-10 moderate effect; 11-20 very large effect; 21-30 extremely large effect.

Time frame:
Week 16
Reported as:
Number · participants
Dermatology Life Quality Index (DLQI) Categories at Week 16
participantsAdalimumab
No Effect105
Small Effect18
Moderate Effect15
Very Large Effect6
Extremely Large Effect0
Missing6
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 4

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-50, 90, and 100 responses are the percentage of participants who achieved at least a 50%, 90%, or 100% reduction (improvement) from baseline in PASI score at Week 4. 100% reduction was considered complete clearance of psoriasis.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 4
percentage of participantsAdalimumab
PASI-5058.6
PASI-9010.6
PASI-1002.0
SecondaryPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-50, 90, and 100 responses are the percentage of participants who achieved at least a 50%, 90%, or 100% reduction (improvement) from baseline in PASI score at Week 4. 100% reduction was considered complete clearance of psoriasis.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 16
percentage of participantsAdalimumab
PASI-5092.6
PASI-9073.3
PASI-10049.3
SecondaryPhysician's Global Assessment (PGA) at Week 4

The PGA is a 7-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant. Categories are as follows: Severe = very marked plaque elevation, scaling, and/or erythema; Moderate to severe = marked plaque elevation, scaling, and/or erythema; Moderate = moderate plaque elevation, scaling, and/or erythema; Mild to moderate = intermediate between moderate and mild; Mild = slight plaque elevation, scaling, and/or erythema; Almost clear = intermediate between mild and clear; Clear = no signs of psoriasis (post-inflammatory hypopigmentation or hyperpigmentation could be present).

Time frame:
Week 4
Reported as:
Number · participants
Physician's Global Assessment (PGA) at Week 4
participantsAdalimumab
Severe3
Moderate to Severe12
Moderate44
Mild to Moderate37
Mild36
Almost Clear11
Clear3
Missing4
SecondaryPhysician's Global Assessment (PGA) at Week 16

The PGA is a 7-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant. Categories are as follows: Severe = very marked plaque elevation, scaling, and/or erythema; Moderate to severe = marked plaque elevation, scaling, and/or erythema; Moderate = moderate plaque elevation, scaling, and/or erythema; Mild to moderate = intermediate between moderate and mild; Mild = slight plaque elevation, scaling, and/or erythema; Almost clear = intermediate between mild and clear; Clear = no signs of psoriasis (post-inflammatory hypopigmentation or hyperpigmentation could be present). The number of participants who achieve a PGA of 'clear' or 'almost clear' at Week 16 was a secondary outcome measure in this study.

Time frame:
Week 16
Reported as:
Number · participants
Physician's Global Assessment (PGA) at Week 16
participantsAdalimumab
Severe1
Moderate to Severe1
Moderate9
Mild to Moderate8
Mild9
Almost Clear44
Clear71
Missing7
SecondaryMean Lipid Profile, Triglycerides, and C-Reactive Protein (CRP) at Baseline and Week 16

Normal values: C-reactive protein (CRP) 0-0.79 mg/dL; cholesterol 30-199 mg/dL; high density lipoprotein (HDL) 40-100 mg/dL; very low density lipoprotein (VLDL) 0-34 mg/dL; low density lipoprotein (LDL) 20-99 mg/dL; triglycerides 50-149 mg/dL.

Time frame:
Baseline, Week 16
Reported as:
Mean · mg/dL
Mean Lipid Profile, Triglycerides, and C-Reactive Protein (CRP) at Baseline and Week 16
mg/dLAdalimumab
C-reactive Protein at Baseline0.6 ± 0.9
C-reactive Protein at Week 160.5 ± 1.6
Cholesterol at Baseline190.7 ± 38.8
Cholesterol at Week 16185.3 ± 33.8
High Density Lipoprotein (HDL) at Baseline41.6 ± 9.7
High Density Lipoprotein (HDL) at Week 1642.6 ± 10.8
Very Low Density Lipoprotein (VLDL) at Baseline37.7 ± 26.3
Very Low Density Lipoprotein (VLDL) at Week 1637.8 ± 20.9
Low Density Lipoprotein (LDL) at Baseline120.8 ± 28.7
Low Density Lipoprotein (LDL) at Week 16120.3 ± 29.9
Triglycerides at Baseline185.3 ± 123.1
Triglycerides at Week 16189.1 ± 104.3
SecondaryMean Homocysteine Levels at Baseline and Week 16

Normal values for homocysteine were 5-13.9 µmol/L.

Time frame:
Baseline, Week 16
Reported as:
Mean · µmol/L
Mean Homocysteine Levels at Baseline and Week 16
µmol/LAdalimumab
Baseline11.6 ± 4.3
Week 1610.9 ± 4.0
SecondaryPercentage of Obese vs. Non-obese (Per Body Mass Index [BMI]) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16

The Body Mass Index (BMI) was used to determine the groups of participants who were overweight and who were considered obese. A BMI of 18.5 to 25 was considered normal range, 25 to 30 as overweight and 30 and above as obesity, in both men and women. Response to treatment in participants with obesity (based on Body Mass Index) versus those without obesity was assessed via PASI-75 response (see Outcome Measure 1 for details) and DLQI score of \<6 (see Outcome Measure 3 for details).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Obese vs. Non-obese (Per Body Mass Index [BMI]) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16
percentage of participantsAdalimumab in Obese ParticipantsAdalimumab in Non-obese Participants
PASI-757692
DLQI <68090
SecondaryPercentage of Obese vs. Non-obese (Per Waist-Hip Ratio) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16

The Waist-Hip Ratio was used to determine the groups of participants who were overweight and who were considered obese. Obesity was defined as a ratio of \>1 for men and \>0.8 for women. Response to treatment in participants with obesity (based on Waist-Hip Ratio) versus those without obesity was assessed via PASI-75 response (see Outcome Measure 1 for details) and DLQI score of \<6 (see Outcome Measure 3 for details).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Obese vs. Non-obese (Per Waist-Hip Ratio) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16
percentage of participantsAdalimumab in Obese ParticipantsAdalimumab in Non-obese Participants
PASI-757791
DLQI <68487
SecondarySerum Levels of Folic Acid at Baseline and Week 4

Normal values for folic acid were 3-15 ng/mL.

Time frame:
Baseline, Week 4
Reported as:
Mean · ng/mL
Serum Levels of Folic Acid at Baseline and Week 4
ng/mLAdalimumab
Baseline18.1 ± 20.0
Week 417.8 ± 11.4
SecondarySerum Levels of Vitamin B6 at Baseline and Week 4

Normal values for vitamin B6 were 18-175 nmol/L.

Time frame:
Baseline, Week 4
Reported as:
Mean · nmol/L
Serum Levels of Vitamin B6 at Baseline and Week 4
nmol/LAdalimumab
Baseline11.2 ± 12.5
Week 411.7 ± 11.6
SecondarySerum Levels of Vitamin B12 at Baseline and Week 4

Normal values for vitamin B12 were 200-1100 pg/mL.

Time frame:
Baseline, Week 4
Reported as:
Mean · pg/mL
Serum Levels of Vitamin B12 at Baseline and Week 4
pg/mLAdalimumab
Baseline542.6 ± 615.5
Week 4439.6 ± 438.9
SecondarySerum Levels of Folic Acid at Baseline and Week 16

Normal values for folic acid were 3-15 ng/mL.

Time frame:
Baseline, Week 16
Reported as:
Mean · ng/mL
Serum Levels of Folic Acid at Baseline and Week 16
ng/mLAdalimumab
Baseline18.2 ± 20.2
Week 1617.9 ± 7.1
SecondarySerum Levels of Vitamin B6 at Baseline and Week 16

Normal values for vitamin B6 were 18-175 nmol/L.

Time frame:
Baseline, Week 16
Reported as:
Mean · nmol/L
Serum Levels of Vitamin B6 at Baseline and Week 16
nmol/LAdalimumab
Baseline11.4 ± 12.6
Week 1611.8 ± 7.6
SecondarySerum Levels of Vitamin B12 at Baseline and Week 16

Normal values for vitamin B12 were 200-1100 pg/mL.

Time frame:
Baseline, Week 16
Reported as:
Mean · pg/mL
Serum Levels of Vitamin B12 at Baseline and Week 16
pg/mLAdalimumab
Baseline541.9 ± 620.5
Week 16441.8 ± 533.8

Adverse events

Collected over Adverse events were collected from start of study through 70 days after the last treatment. Treatment duration was 15 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—1/150 (0.7%)86/150 (57.3%)
Most frequent serious events
Most frequent serious events
EventAdalimumab
CholelithiasisGastrointestinal disorders1/150
Most frequent other events
Showing 10 of 60
Most frequent other events
EventAdalimumab
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders17/150
HyperglycemiaMetabolism and nutrition disorders16/150
ArthralgiaMusculoskeletal and connective tissue disorders10/150
HeadacheNervous system disorders8/150
HypertriglyceridemiaMetabolism and nutrition disorders7/150
Application site pain and/or pruritusGeneral disorders7/150
PharyngitisRespiratory, thoracic and mediastinal disorders6/150
FatigueGeneral disorders4/150
AnemiaBlood and lymphatic system disorders3/150
Hypervitaminosis B12Metabolism and nutrition disorders3/150

Baseline characteristics

Age Continuous
Age Continuous(years)Adalimumab
Mean44.6 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female37
Male113
Region of Enrollment
Region of Enrollment(participants)Adalimumab
Mexico150
08

Study locations

8 sites
  • Site Reference ID/Investigator# 50942
    Circuito Comercial Satelite, Mexico
  • Site Reference ID/Investigator# 40964
    Iztapalapa, 04230, Mexico
  • Site Reference ID/Investigator# 50943
    Mexico City, 06780, Mexico
  • Site Reference ID/Investigator# 40965
    Monterrey, 64460, Mexico
  • Site Reference ID/Investigator# 40962
    Monterrey, 64718, Mexico
  • Site Reference ID/Investigator# 40662
    Toluca de Lerdo, 50120, Mexico
  • Site Reference ID/Investigator# 41062
    Toluca de Lerdo, 50120, Mexico
  • Site Reference ID/Investigator# 40963
    Zapopan, 45190, Mexico
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2010
First posted
Dec 23, 2010
Start
Oct 2010
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Mar 11, 2013
Last update
Mar 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01265823
Responsible party
Sponsor
First posted
Dec 23, 2010
Start date
Oct 2010
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Mar 11, 2013
Last update
Mar 11, 2013

Study contacts

Jose-Luis Canadas, Medical Director, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion